ReviewThe Journal of allergy and clinical immunology2017
Biomarkers in connective tissue diseases.
Review in The Journal of allergy and clinical immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.PloS one · 2020Trial
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- Connective Tissue Disorder-Induced Diffuse Alveolar Hemorrhage: A Comprehensive Review with an Emphasis on Airway and Respiratory Management.Life (Basel, Switzerland) · 2025Review
- Systemic Lupus Erythematosus and Cytokine Storm.Advances in experimental medicine and biology · 2024Review
- Autoantibody Profiling Using Human Autoantigen Protein Array and AlphaScreen.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Hypoxia-Inducible Factor-1α (HIF-1α) as a Biomarker for Changes in Microcirculation in Individuals with Systemic Sclerosis.Dermatology and therapy · 2023Article
- Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation.Annals of the rheumatic diseases · 2023Article
- Incompatibilities between common mtDNA variants in human disease.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.Journal of inflammation research · 2023Review
- Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment approach.Frontiers in immunology · 2023Article
- Alcohol abuse may increase the risk of autoimmune connective tissue disease: a nationwide population-based cohort study.Frontiers in psychiatry · 2023Article
- Biomarkers of disease progression in people with psoriasis: a scoping review.The British journal of dermatology · 2022Article
- Personalized Medicine in the Field of Inflammatory Skin Disorders.Journal of personalized medicine · 2022Article
- Cholinergic anti-inflammatory pathway and connective tissue diseases.Inflammopharmacology · 2021Review
- Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.PloS one · 2021Article
- Cytokines in gingivocrevicular fluid of rheumatoid arthritis patients: A review of the literature.Oral diseases · 2019Review
- Biomarkers as drug development tools: discovery, validation, qualification and use.Nature reviews. Rheumatology · 2018Review
- Autoimmune connective tissue diseases in the COVID-19 pandemic.Clinics in dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Autoimmune connective tissue diseases are clinically variable, making biomarkers desirable for assessing future disease risk, supporting early and accurate diagnosis, monitoring disease activity and progression, selecting therapeutics, and assessing treatment response. Because of their correlations with specific clinical characteristics and often with disease progression, autoantibodies and other soluble mediators are considered potential biomarkers. Additional biomarkers might reflect downstream pathologic processes or appear because of ongoing inflammation and damage. Because of overlap between diseases, some biomarkers have limited specificity for a single autoimmune connective tissue disease. This review describes select current biomarkers that aid in the diagnosis and treatment of several major systemic autoimmune connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and anti-neutrophil cytoplasmic antibody-associated vasculitides. Newly proposed biomarkers that target various stages in disease onset or progression are also discussed. Newer approaches to overcome the diversity observed in patients with these diseases and to facilitate personalized disease monitoring and treatment are also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.